Skip to main content
Gynecologic Cancer Breast Cancer

Breast Cancer

Hormonal management after risk-reducing surgery in TNBC survivors

Is HRT appropriate after risk-reducing surgery in BRCA mutation carriers with a history of triple-negative breast cancer? What do current international guidelines, evidence, and expert recommendations suggest?

Read more

Editor's Choice

GLP-1 drugs may improve survival of people with brain metastases

People with cancer brain metastases and type 2 diabetes might derive a survival benefit from the use of glucagon-like peptide-1 receptor agonists.

Colonic metastasis from breast cancer

Although colonic metastases from breast cancer are extremely rare, it is important for patients with a history of breast cancer who present with GI symptoms to undergo prompt endoscopic evaluation.

Managing breast cancer brain metastases

Explore the current knowledge of breast cancer brain metastases, from metastatic mechanisms to tumor microenvironment interactions, and learn how this understanding is driving diagnostic and therapeutic developments.

Chemotherapy-associated coronary thrombosis in breast cancer

This case of subacute inferolateral myocardial infarction secondary to coronary thrombosis occurring after adjuvant doxorubicin–cyclophosphamide therapy in a patient with breast cancer underscores the need for vigilance for uncommon, yet life-threatening, complications.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsor:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Watch now
Video

Case Studies

Colonic metastasis from breast cancer

Although colonic metastases from breast cancer are extremely rare, it is important for patients with a history of breast cancer who present with GI symptoms to undergo prompt endoscopic evaluation.

Chemotherapy-associated coronary thrombosis in breast cancer

This case of subacute inferolateral myocardial infarction secondary to coronary thrombosis occurring after adjuvant doxorubicin–cyclophosphamide therapy in a patient with breast cancer underscores the need for vigilance for uncommon, yet life-threatening, complications.

Metachronous multiple primary cancers

A rare occurrence of four primary malignancies – bilateral breast cancer, ovarian cancer, and undifferentiated high-grade pleomorphic sarcoma. Could the patient have a hereditary cancer syndrome?

At a glance: The DESTINY-Breast trials

The antibody–drug conjugate trastuzumab deruxtecan is being investigated in the DESTINY-Breast trials for the treatment of breast cancer.

Read more

Current Reviews

Niraparib in breast cancer: evidence-based perspective on translational progress

Breast cancer is the most prevalent malignancy in women throughout the world, with a high level of heterogeneity concerning the subtypes, posing challenges to long-term treatment success. Among the emerging therapeutic strategies, poly …

Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale

Antibody-drug conjugates (ADCs) represent a major advance in breast cancer therapy, with trastuzumab deruxtecan and sacituzumab govitecan emerging as leading agents targeting distinct tumor antigens and employing different linker-payload designs.

Breast cancer inequities: the intersectional role of social epidemiology and tumor biology

Breast cancer disparities in outcomes remain a persistent challenge in the USA, with survival influenced by neighborhood context, access to resources, and the applicability of existing scientific evidence across populations. These disparities …

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide and a leading cause of cancer-related mortality [ 1 ].

Episode 15: Breastfeeding after breast cancer

POSITIVEly reassuring results from a clinical trial

The POSITIVE trial previously showed that women with breast cancer can safely interrupt endocrine therapy in order to become pregnant. But what about breastfeeding - is that possible and safe for the mother and baby?

Women can take heart from the latest findings, says Dr. Cristina Saura, as she takes us through these important clinical updates.

Dr. Cristina Saura
Listen now
Podcast

Further Reading

Factors associated with central venous port implantation during breast cancer perioperative chemotherapy: a Japanese database study

Breast cancer prevalence has been increasing worldwide, including Japan [ 1 ]. In early-stage breast cancer, intravenous vesicant chemotherapy is often administered perioperatively as the primary treatment [ 2 ]. Extravasation is the most serious …

Impact of background parenchymal enhancement on the diagnosis of enhancing lesions in breast MRI: a systematic approach

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has the highest sensitivity for detecting breast cancer among current clinical imaging modalities [ 1 ]. However, after administration of intravenous contrast media, in addition to …

Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale

Antibody-drug conjugates (ADCs) represent a major advance in breast cancer therapy, with trastuzumab deruxtecan and sacituzumab govitecan emerging as leading agents targeting distinct tumor antigens and employing different linker-payload designs.

Image Credits
Hormone replacement therapy/© RFBSIP / stock.adobe.com (symbolic image with model), Incretin mimetic injectors/© aprott / Getty Images / iStock, Abdominal CT of breast cancer patient with colonic metastasis/© 2026, Matteo Matteucci et al, Int J Colorectal Dis, Paper illustration of multiple brain tumors/© freshidea / Stock.adobe.com, Angiography showing total occlusion of LAD and LCX/© 2026, Oya Imadoglu et al, BMC Cardiovasc Disord, Stylized collage of women/© (M) VictoriaBar / Getty Images / iStock, Man standing in a supermarket aisle and reading the label on a grocery item/© Giselleflissak / Getty Images / iStock (symbolic image with model), Older man sitting on the edge of a bed/© andreswd / E+ / Getty Images (symbolic image with model), Mammogram image on a screen/© Valerii Apetroaiei / stock.adobe.com, Heap of blue, white, and beige pills and capsules/© AlexRaths / Getty Images / iStock, CAR T-cell attacking cancer cells/© Springer Medicine, June 2024, under a creative commons [CCBY] license., Histology of patient with multiple primary cancers/© 2025, Rongze Sun et al, J Cancer Res Clin Oncol, Crystal ball on pink background/© EyeEm Mobile GmbH / Getty Images / iStock, Medicine Matters Podcast promo image/© Springer Medizin GmbH, Dart hitting center of target/© Ramita / Generated with AI / Stock.adobe.com, CAR T cells attacking cancer cells illustration/© Artur / stock.adobe.com